Betalin Therapeutics licensed the novel EMP technology developed at The Hebrew University of Jerusalem, Israel, in an exclusive worldwide agreement in 2015. The Hebrew University continues to partner with Betalin Therapeutics to support the research and development.
Based on promising in vitro results and preliminary in vivo results, Betalin Therapeutics has recently submitted a pre-pre-IND (Investigational New Drug) application to the Food and Drug Administration (FDA). Following the FDA's positive response, Betalin Therapeutics is now preparing the pre-IND meeting on its way towards IND submission.
Betalin Therapeutics is currently raising funding in order to further optimize the therapy in animal models, complete submission of the IND application to the FDA, and proceed to clinical trials. Betalin Therapeutics was recently awarded a competitive matching grant from the Office of the Chief Scientist, doubling the value of investments made at this stage.
Currently, no events have been added to this timeline yet.
Be the first one to add some.
VP Research and Development
Advisory Board Member
Senior Scientist/ Lab manager
Shuki Joshua Hershcovich
Betalin Therapeutics Wins Startup Competition at MIXiii Biomed 2017
Engineered Micro Pancreas Raises Hope for Type 1 Diabetes Treatment
Documentaries, videos and podcasts
Jan 25, 2016
Feb 26, 2018